|
Michael G. Carter M.D. age 68 was appointed to the Board of Directors in May 2006 and is a member of the Compensation Committee. Dr. Carter currently is a non-executive director of Micromet Inc.; Santarus Inc.; and Fulcrum Pharma Plc. He is non-executive chairman of Metris Therapeutics Ltd. a biotechnology firm specializing in women's healthcare. He is a member of the Advisory Board of Paul Capital Royalty Fund and is a venture partner with SV Life Sciences Advisers LLP. He served on the Pharmaceutical Board of Zeneca Pharmaceuticals a predecessor company of AstraZeneca and held various positions within Zeneca including International Marketing Director and International Medical Director. Under his direction Zeneca developed and launched numerous drugs including Casodex the most widely prescribed anti-androgen for prostate cancer therapy in the U.S. Zoladex an LHRH analogue for prostate cancer and breast cancer; and Arimidex the first new generation aromatase inhibitor for breast cancer. Dr. Carter also contributed to the post-marketing development of tamoxifen the first selective estrogen receptor modulator approved for the treatment of breast cancer. Dr. Carter received his medical degree from Sheffield University Medical School and a BPharm degree from the London University School of Pharmacy. He is a Fellow of the Royal Pharmaceutical Society of the Royal College of Physicians of Edinburgh and of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He has served as a member of the Medicines Commission of the United Kingdom. | 